JOURNAL of
ONCOLOGICAL
SCIENCES

EDITORIAL

By 2022, Cancer is Now a More Chronic Disease with Chronic Difficulties to Go Along with It
Received Date : 29 Mar 2022
Accepted Date : 31 Mar 2022
Available Online : 13 Apr 2022
Doi: 10.37047/jos.2022-90068 - Article's Language: EN
J Oncol Sci. 2022;8(1):1-6
This is an open access article under the CC BY-NC-ND license
ABSTRACT
Cancer is a disease in which some body cells with genetic or epigenetic changes become capable of replicating and invading other regions of the body uncontrollably. Numerous functional abilities and features are acquired by these cells during this multistage neoplastic process. In the last 20 years, many agents have been discovered and used in the fight against cancer. However, the use of these drugs in appropriate patient groups is still a serious problem. Many cancer types are on the way to becoming chronic diseases; conscientious physicians who are unable to provide appropriate treatment due to economic factors and other reasons face an additional burden.
KAYNAKLAR
  1. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. [Crossref]  [PubMed] 
  2. Yuan S, Norgard RJ, Stanger BZ. Cellular plasticity in cancer. Cancer Discov. 2019;9(7):837-851. [Crossref]  [PubMed]  [PMC] 
  3. Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 2016;8(9):a019505. [Crossref]  [PubMed]  [PMC] 
  4. Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science. 2017;357(6348):eaal2380. [Crossref]  [PubMed]  [PMC] 
  5. Jones PA, Issa JP, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17(10):630-641. [Crossref]  [PubMed] 
  6. Thomas S, Izard J, Walsh E, et al. The host microbiome regulates and maintains human health: a primer and perspective for non-microbiologists. Cancer Res. 2017;77(8):1783-1812. [Crossref]  [PubMed]  [PMC] 
  7. Dzutsev A, Badger JH, Perez-Chanona E, et al. Microbes and cancer. Annu Rev Immunol. Apr 2017;35:199-228. [Crossref]  [PubMed] 
  8. Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome, cancer, and cancer therapy. Nat Med. 2019;25(3):377-388. [Crossref]  [PubMed] 
  9. Birch J, Gil J. Senescence and the SASP: many therapeutic avenues. Genes Dev. 2020;34(23-24):1565-1576. [Crossref]  [PubMed]  [PMC] 
  10. Wang B, Kohli J, Demaria M. Senescent cells in cancer therapy: friends or foes? Trends Cancer. 2020;6(10):838-857. [Crossref]  [PubMed] 
  11. Laetsch TW, Hong DS. Tropomyosin receptor kinase inhibitors for the treatment of TRK fusion cancer. Clin Cancer Res. 2021;27(18):4974-4982. [Crossref]  [PubMed] 
  12. Doebele RC, Drilon A, Paz-Ares L, et al; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):271-282. [Crossref] 
  13. Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531-540. [Crossref] 
  14. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-134. [Crossref]  [PubMed] 
  15. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382-1392. [Crossref]  [PubMed] 
  16. Drew Y, Kaufman B, Banerjee S, et al. Phase II study of olaparib 1 durvalumab (MEDIOLA): updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC). Ann Oncol. 2019;(suppl):V485-486. [Crossref] 
  17. Cortesi L, Rugo HS, Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 2021;16(3):255-282. [Crossref]  [PubMed]  [PMC] 
  18. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327-344. [Crossref]  [PubMed] 
  19. Cortés J, Kim SB, Chung WP, et al. LBA1 trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study. Ann Oncol. Sep 2021;32:S1287-S1288. [Crossref] 
  20. Miglietta F, Griguolo G, Bottosso M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer. 2021;7(1):137. [Crossref]  [PubMed]  [PMC] 
  21. AstraZeneca. ENHERTU® (fam-trastuzumab deruxtecan-nxki) significantly improved both progression-free and overall survival in DESTINY-Breast04 trial in patients with HER2-low metastatic breast cancer. 21 February 2022. [Link] 
  22. Bardia A, Hurvitz SA, Tolaney SM, et al; ASCENT Clinical Trial Investigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529-1541. [Crossref]  [PubMed] 
  23. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125-1135. [Crossref]  [PubMed]  [PMC] 
  24. Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint ınhibitors. J Clin Oncol. 2021;39(22):2474-2485. [Crossref]  [PubMed] 
  25. Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH Jr. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27(Suppl 2):S87-S97. [Crossref]  [PubMed]  [PMC] 
  26. van den Bulk J, Verdegaal EM, de Miranda NF. Cancer immunotherapy: broadening the scope of targetable tumours. Open Biol. 2018;8(6):180037. [Crossref]  [PubMed]  [PMC] 
  27. Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of immunotherapy combination strategies in cancer. Cancer Discov. 2021;11(6):1368-1397. [Crossref]  [PubMed]  [PMC] 
  28. Dhar R, Seethy A, Singh S, et al. Cancer immunotherapy: recent advances and challenges. J Cancer Res Ther. 2021;17(4):834-844. [Crossref]  [PubMed]